CD1d remodels the tumor-infiltrating myeloid populations controlling antitumor immunity
Journal of Experimental Medicine · 07.09.2026 · 223 (9)
DOI: 10.1084/jem.20260216 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 13.08.2026. Verfasst von Lauren Evans und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Inflammation Biology, Centre for Inflammation Biology and Cancer Immunology, King's College London, London, UK. Hauptthemen laut MEDLINE: Myeloid Cells, Antigens, CD1d, Breast Neoplasms. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Medical Research Council, UK Government, UK Biotechnology and Biological Sciences Research Council.
Abstract (Originalsprache)
Myeloid cells play crucial roles in cancer progression, influencing tumor growth, metastasis, and response to immunotherapy. The mechanisms shaping their diverse functions in the tumors remain poorly understood and may offer therapeutic opportunities. Here, we identify the lipid-presenting molecule CD1d as a regulator of tumor progression and myeloid heterogeneity in the tumor microenvironment. Using several mouse models of breast cancer, we demonstrate that genetic deletion or antibody-mediated targeting of CD1d leads to reduced tumor growth, altered immune infiltration, and improved efficacy of anti-PD-1 immunotherapy. Specifically, CD1d targeting reshapes the intratumoral myeloid compartment, enhancing proinflammatory programs and resulting in accumulation of inflammatory monocytes. The CD1d-dependent control of myeloid cell functional differentiation is cell-intrinsic and conserved in human and mouse. Through single-cell RNA sequencing, we define the transcriptional landscape associated with CD1d deficiency and derive a gene signature that correlates with clinical outcomes and response to immunotherapy in breast cancer patients. Thus, CD1d could provide a potential target to alter tumor-infiltrating myeloid populations and enhance immunotherapy responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Inflammation Biology, Centre for Inflammation Biology and Cancer Immunology, King's College London, London, UK.
- The Francis Crick Institute , London, UK.
- Department of Genetics, Evolution and Environment, UCL Genetics Institute, University College London, London, UK.
- Cancer Bioinformatics, Faculty of Life Sciences and Medicine, King's College London, London, UK.
ORCID-Profile: Lauren Evans, Maria Conde Poole, Cenk Celik, Harshita Mishra, Michael J Pitcher, Anita Grigoriadis, Maria Secrier, Patricia Barral
Förderung
- UK Medical Research Council
- UK Government
- UK Biotechnology and Biological Sciences Research Council
- Wellcome Trust
- Guy's Cancer Charity
- The Francis Crick Institute
- UK Research and Innovation
- Department for Science, Innovation, and Technology
Zitieren
APA
Evans, L., Conde Poole, M., Celik, C., Mishra, H., Pitcher, M. J., Grigoriadis, A., Secrier, M., & Barral, P. (2026). CD1d remodels the tumor-infiltrating myeloid populations controlling antitumor immunity. Journal of Experimental Medicine, 223(9). https://doi.org/10.1084/jem.20260216
Vancouver
Evans L, Conde Poole M, Celik C, Mishra H, Pitcher MJ, Grigoriadis A, et al. CD1d remodels the tumor-infiltrating myeloid populations controlling antitumor immunity. Journal of Experimental Medicine. 2026;223(9). doi:10.1084/jem.20260216
BibTeX
@article{Evans2026,
author = {Evans, Lauren and Conde Poole, Maria and Celik, Cenk and Mishra, Harshita and Pitcher, Michael J and Grigoriadis, Anita and Secrier, Maria and Barral, Patricia},
title = {CD1d remodels the tumor-infiltrating myeloid populations controlling antitumor immunity},
journal = {Journal of Experimental Medicine},
year = {2026},
volume = {223},
number = {9},
doi = {10.1084/jem.20260216}
}
EUVIMED